Clinical Research Directory

Key Inclusion Criteria: * Diagnosis of acquired primary chronic neutropenia (CN) disorder ≥6 months prior to the screening visit (Week -2 up to Week 1) that is not attributable to medications, active or recent infections, or malignancy. * On G-CSF for ≥6 months; stable dose prior to start of mavorixafor dosing. * Most recent bone marrow examination, within 3 years, shows no evidence of malignancy/high risk of malignant transformation. Key Exclusion Criteria: * Participant is incapacitated and unable to comply with protocol-specific requirements. * A diagnosis of any of the following: 1. Aplastic anemia 2. Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome 3. CN other than CIN or AIN * A medical or personal condition that may potentially compromise the safety of the participant, may preclude the participant's successful completion of the clinical study, or could, in the opinion of the Investigator or the Medical Monitor, interfere with the objectives of the study. * Participant is currently taking or has taken an investigational drug \<30 days prior to the screening visit, or 5 half-lives, whichever is longer. * Participant is pregnant or breastfeeding. Note: Other protocol-defined inclusion and exclusion criteria may apply.